TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $20.00 price objective on the stock.
TransCode Therapeutics Stock Performance
NASDAQ RNAZ opened at $0.78 on Thursday. The firm has a 50-day moving average of $5.54 and a 200-day moving average of $237.59. TransCode Therapeutics has a 52-week low of $0.65 and a 52-week high of $66.33.
About TransCode Therapeutics
Recommended Stories
- Five stocks we like better than TransCode Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Where to Find Earnings Call Transcripts
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to Invest in Biotech Stocks
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.